Survival in Patients with Non-Hodgkin's Lymphoma: A Comparison of Treatments
Author Information
Author(s): Messori A, Vaiani M, Trippoli S, Rigacci L, Jerkeman M, Longo G
Primary Institution: Drug Information Center Azienda Ospedaliera Careggi, Firenze, Italy
Hypothesis
Do third generation chemotherapy regimens improve survival compared to the standard CHOP regimen in patients with intermediate or high grade non-Hodgkin lymphoma?
Conclusion
Third generation chemotherapy regimens do not improve survival compared to CHOP in patients with intermediate or high grade non-Hodgkin lymphoma.
Supporting Evidence
- Third generation chemotherapy did not prolong survival compared to CHOP.
- The relative death risk for third generation regimens vs. CHOP was 0.92.
Takeaway
Doctors wanted to see if a new type of cancer treatment helped people live longer than the old one, but it turns out it didn't make a difference.
Methodology
A meta-analysis of randomized controlled trials published in English from 1970 to 1999, including 5 trials and patient-level information.
Limitations
The study only included trials published in English and may not represent all available data.
Participant Demographics
Patients with intermediate or high grade non-Hodgkin lymphoma.
Statistical Information
P-Value
0.23
Confidence Interval
95%CI: 0.80 to 1.06
Statistical Significance
p=0.23
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website